CoChat

Implementation of pre‐seasonal sublingual immunotherapy with a five‐grass pollen tablet during optimal dosage assessment

Open access
Horak, F., Jaeger, S., Worm, M., Melac, M., Didier, A. · 2009 · Clinical & Experimental Allergy
Cited by 35

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Summary: Background The optimal dose (300IR) of a five‐grass pollen sublingual immunotherapy tablet in terms of efficacy was previously demonstrated from the first pollen season. Objective Here, we aim to confirm whether this dose remained optimal during the peak of the pollen season by assessing the efficacy and quality of life data. Methods A total of 628 subjects with grass pollen rhinoconjunctivitis were randomized in a double‐blind, placebo‐controlled, multi‐centre, pan‐European trial. Subjects received once‐daily tablets (Stallergenes, Antony, France) of 100IR, 300IR, 500IR or placebo, starting 4 months before and throughout the 2005 grass pollen season. The pollen season was defined as the first day of 3 consecutive days with a grass pollen count above 30 grains/m 3 of air, recorded using Hirst‐type volumetric pollen traps, to the last day before 3 consecutive days with a pollen count below 30 grains/m 3. Results The grass pollen season lasted an average of 30 days, with a peak of 12 days. The mean treatment duration before the grass pollen season was similar in the four treatment groups (121.4±31.1 to 128.6±15.4 days in the safety population). Both the 300IR and 500IR groups had highly significant improvements in Rhinoconjunctivitis Total Symptom Score (RTSS) vs. placebo at the peak pollen season (P=0.0005 and 0.0014, respectively), which agreed with improvements in RTSS in the primary evaluations. The average RTSS scores were slightly elevated during the peak pollen season in all treatment groups. The overall Rhinoconjunctivitis Quality of Life Questionnaire score confirmed the optimal dosage 300IR at peak (P<0.0001) and at the end (P 0.0031) of the pollen season. All doses were well tolerated. Conclusion At the peak pollen season, the efficacy and quality of life data for both 300IR and 500IR groups was significantly improved vs. the placebo group. These results confirm the conclusions of the primary evaluations and validate the use of 300IR tablets for clinical practice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2222.2008.03153.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 35

Metadata

Authors
Horak, F., Jaeger, S., Worm, M., Melac, M., & Didier, A.
Venue
Clinical & Experimental Allergy
Publisher
Wiley
Published
2009-01-28
Volume
39
Issue
3
Pages
394-400
ISSN
  • 0954-7894 (ISSN-L)
  • 1365-2222
OpenAlex
W2129356951
Cited by
35
References
2
FWCI
4.25
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Implementation of pre‐seasonal sublingual immunotherapy with a five‐grass pollen tablet during optimal dosage assessment. https://app.cochat.ai/papers/10.1111/j.1365-2222.2008.03153.x
The paper
Horak, F., Jaeger, S., Worm, M., Melac, M., & Didier, A. (2009). Implementation of pre‐seasonal sublingual immunotherapy with a five‐grass pollen tablet during optimal dosage assessment. Clinical & Experimental Allergy. https://doi.org/10.1111/j.1365-2222.2008.03153.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.